Related references
Note: Only part of the references are listed.Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Death Receptor Agonists as a Targeted Therapy for Cancer
Jeffrey Wiezorek et al.
CLINICAL CANCER RESEARCH (2010)
An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
Rajeshwari Sridhara et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
mToR signaling and drug development in cancer
Janet Dancey
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Personalized Medicine Enters the US Marketplace: KRAS, Anti-EGFR Monoclonal Antibodies, and Colon Cancer
Ronald Lieberman
AMERICAN JOURNAL OF THERAPEUTICS (2009)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
PI3K Regulatory Subunits Lose Control in Cancer
Inma Martin-Berenjeno et al.
CANCER CELL (2009)
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Bijay S. Jaiswal et al.
CANCER CELL (2009)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
Taroh Satoh et al.
CLINICAL CANCER RESEARCH (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
No Evidence for the JAK2 (V617F) or JAK2 Exon 12 Mutations in Primary Mediastinal Large B-cell Lymphoma
David Wu et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
BRAF Signaling and Targeted Therapies in Melanoma
Nathalie Dhomen et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
STAT5 regulation of BCL10 parallels constitutive NFκB activation in lymphoid tumor cells
Zsuzsanna S. Nagy et al.
MOLECULAR CANCER (2009)
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
Nathan T. Ihle et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Helena Linardou et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Focus Issue: Demystifying mTOR Signaling
Nancy R. Gough
SCIENCE SIGNALING (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Immunoregulatory functions of mTOR inhibition
Angus W. Thomson et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M. Crump et al.
ANNALS OF ONCOLOGY (2008)
Therapeutic activity of mTOR inhibitors in mantle cell lymphoma - Clues but no clear answers
Anas Younes
AUTOPHAGY (2008)
IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis
Ferenc A. Scheeren et al.
BLOOD (2008)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
Ezogelin Oflazoglu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
Stephen M. Ansell et al.
CANCER (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway
S. Wang
ONCOGENE (2008)
Class IPI3K in oncogenic cellular transformation
L. Zhao et al.
ONCOGENE (2008)
PI3K/Akt: getting it right matters
T. F. Franke
ONCOGENE (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L. Bartlett et al.
BLOOD (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
B. Belinda Ding et al.
BLOOD (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2007)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Michael J. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma
C. Renne et al.
LEUKEMIA (2007)
A role for mammalian target of rapamycin in regulating T cell activation versus anergy
Yan Zheng et al.
JOURNAL OF IMMUNOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206
Kristie A. Blum et al.
LEUKEMIA & LYMPHOMA (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis
V. Joliot et al.
ONCOGENE (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein
I Melzner et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation
MA Weniger et al.
ONCOGENE (2006)
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma
A Younes et al.
BLOOD (2006)
Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma
I Melzner et al.
LEUKEMIA (2006)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dose escalation trial designs based on a molecularly targeted endpoint
S Hunsberger et al.
STATISTICS IN MEDICINE (2005)
STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
U Holtick et al.
LEUKEMIA (2005)
HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3
S Nagel et al.
LEUKEMIA (2005)
Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR
A Dutton et al.
JOURNAL OF PATHOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
JP Leonard et al.
CLINICAL CANCER RESEARCH (2004)
Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma
JA Morrison et al.
CANCER RESEARCH (2004)
Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma
HM Amin et al.
ONCOGENE (2004)
Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy
A Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO)
M Jücker et al.
LEUKEMIA (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
STAT3 is constitutively activated in Hodgkin cell lines
D Kube et al.
BLOOD (2001)
Share Paper
